Vizionfocus Valuation
Is 4771 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4771 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4771 (NT$190) is trading above our estimate of fair value (NT$154.3)
Significantly Below Fair Value: 4771 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4771?
Key metric: As 4771 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4771's PE Ratio? | |
|---|---|
| PE Ratio | 16.1x |
| Earnings | NT$684.94m |
| Market Cap | NT$11.00b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 9.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 4771's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.5x | ||
4129 United Orthopedic | 20.8x | n/a | NT$9.3b |
6782 Visco Vision | 21.3x | 22.2% | NT$13.2b |
1786 SciVision Biotech | 30.4x | n/a | NT$6.6b |
4107 Bioteque | 17.7x | n/a | NT$8.8b |
4771 Vizionfocus | 16.1x | n/a | NT$11.0b |
Price-To-Earnings vs Peers: 4771 is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (22.5x).
Price to Earnings Ratio vs Industry
How does 4771's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 4771 is good value based on its Price-To-Earnings Ratio (16.1x) compared to the TW Medical Equipment industry average (19.5x).
Price to Earnings Ratio vs Fair Ratio
What is 4771's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4771's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NT$190.00 | NT$287.50 +51.3% | 5.7% | NT$304.00 | NT$271.00 | n/a | 2 |
| Nov ’25 | NT$201.00 | NT$287.50 +43.0% | 5.7% | NT$304.00 | NT$271.00 | n/a | 2 |
| Oct ’25 | NT$233.50 | NT$287.50 +23.1% | 5.7% | NT$304.00 | NT$271.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Universal Vision Biotechnology
NT$18.0b
Operates a chain of eye care clinics in Taiwan and China.
3218
NT$212.50
7D
-1.4%
1Y
-27.0%
Ma Kuang Healthcare Holding
NT$1.3b
An investment holding company, provides medical services in Taiwan and internationally.
4139
NT$30.40
7D
-0.2%
1Y
-17.8%
Pacific Hospital Supply
NT$6.4b
Manufactures, processes, and sells medical disposable products and equipment in Taiwan.
4126
NT$88.60
7D
-0.3%
1Y
5.2%